Purchase Order 75N93018P01377

<p>The National Cancer Institute awarded a purchase order to Trustees of Indiana University for the production of 40 liters of high-titer clinical-grade lentiviral vector stock on September 23, 2016, with a ceiling value of $198,307.85 and firm fixed pricing. Performance is located in Indianapolis, Indiana. The period of performance is one year, with an ultimate completion date of April 30, 2019. The award includes a modification to modify the terms and conditions.</p>

<p>The National Institute of Allergy and Infectious Diseases awarded a purchase order to Research Institute At Nationwide Children's Hospital valued at $15,000 on June 27, 2017, for high-quality AAV viral preparations with different vector serotypes (AAV1, AAV6) that have been purified and passed rigorous quality control standards. Work is performed in Columbus, Ohio. The order was firm fixed price with an ultimate completion date of July 30, 2017.</p>

The National Institute of Allergy and Infectious Diseases issued a delivery order to International AIDS Vaccine Initiative Inc. on August 28, 2018, with a ceiling value of $26.065 million for manufacture of human flu challenge material. Work is performed in New York, NY under Cost Plus Fixed Fee pricing, with an ultimate completion date of May 14, 2028. The delivery order supports IAVI's vaccine development and manufacturing services, including process development, analytical testing, cGMP...

The National Institute of Allergy and Infectious Diseases issued a delivery order to International AIDS Vaccine Initiative Inc. on May 15, 2018, with a ceiling value of $55,936.00 under a Cost Plus Fixed Fee pricing structure. Place of performance is New York, NY. The ultimate completion date is May 14, 2019. The delivery order funds base task order work designated as OBRA-2, supporting vaccine development and related services within IAVI's research and development portfolio for infectious...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded a delivery order contract valued at $8.3 million to International AIDS Vaccine Initiative Inc. (IAVI) on September 26, 2023, for the manufacture of influenza virus human challenge material to support Phase I and II clinical testing. The contract utilizes a cost-plus-fixed-fee pricing structure and carries no set-aside designation. Work will be performed in Bowling Green, New York, with an ultimate completion date of...

The National Institute of Allergy and Infectious Diseases issued a delivery order to The Geneva Foundation on January 11, 2019, with a ceiling value of $142,614.09 under the In Vitro Assessments of Antimicrobial Activity (IVAAA) indefinite delivery vehicle for in vitro assessments of antimicrobial activity. The order requires determination of antiviral inhibitory effects and cytotoxicity of experimental antiviral compounds against viruses, including rapidly emerging viruses utilizing the same...

This is a delivery order awarded by the Department of Health and Human Services' National Institutes of Health National Heart Lung and Blood Institute to the Trustees of Indiana University, doing business as Indiana University Iupui, a non-profit organization and state-controlled institution of higher learning. The $358,200.00 delivery order is for Task Area B, Core Scientific Activities for the NATIONAL GENE VECTOR BIOREPOSITORY AND COORDINATING CENTER (NGVB) program. The contract has a...

The National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) awarded a $12,810 firm-fixed-price purchase order contract to the University of Florida Division of Sponsored Research to generate specific AAV virus strains (CV5379 and CV5380) for use in ocular infection experiments. This contract was a sole-source award with no set-aside designation, as the University of Florida Ocular Gene Therapy Core has the unique expertise and capability to...

This is a firm fixed-price purchase order contract awarded by the National Cancer Institute, a civilian agency within the Department of Health and Human Services, to the Trustees of Indiana University, doing business as Indiana University, to manufacture and conduct biosafety testing of a gamma retroviral vector. The contract has a ceiling value of $120,710.88 and a period of performance ending on March 21, 2017. It does not have a set-aside designation. Indiana University is a major public...

This federal contract award is for the National Gene Vector Biorepository and Coordinating Center (NGVB) program, which supports ongoing gene therapy research. The Department of Health and Human Services' National Institutes of Health National Heart Lung and Blood Institute awarded a $403,055.34 firm fixed-price delivery order contract to the Trustees of Indiana University, doing business as Indiana University IUPUI, a state-controlled institution of higher learning. The contract does not...